ClinicalTrials.gov record
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

ClinicalTrials.gov ID: NCT04144348

Public ClinicalTrials.gov record NCT04144348. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, and to Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

Study identification

NCT ID
NCT04144348
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
ModernaTX, Inc.
Industry
Enrollment
51 participants

Conditions and interventions

Interventions

  • Placebo Biological
  • mRNA-1653 Biological

Biological

Eligibility (public fields only)

Age range
12 Months to 49 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 3, 2019
Primary completion
Dec 19, 2022
Completion
Dec 19, 2022
Last update posted
Feb 2, 2023

2019 – 2022

United States locations

U.S. sites
19
U.S. states
12
U.S. cities
19
Facility City State ZIP Site status
Central Research Associates Inc Birmingham Alabama 35205
Meridian Clinical Research Washington D.C. District of Columbia 20016
Clinical Research Prime Idaho Falls Idaho 83404
Heartland Research Associates LLC El Dorado Kansas 67042
Heartland Research Associates LLC Newton Kansas 67114
MedPharmics Metairie Louisiana 70006
Meridian Clinical Research, LLC Lincoln Nebraska 68510
Meridian Clinical Research Norfolk Nebraska 68701
Meridian Clinical Research, LLC Omaha Nebraska 68134
UHS Primary Care Binghamton New York 13901
Child Healthcare Associates Liverpool New York 13090
Child Healthcare Assoc. Syracuse New York 13057
Duke Vaccine and Trials Unit Durham North Carolina 27710
Ohio Pediatric Research Assn Inc Dayton Ohio 45414
Sanford Children's Hospital Sioux Falls South Dakota 57117
Crossroads Clinical Research Corpus Christi Texas 78413
University of Texas Medical Branch (UTMB) Galveston Texas 77555
Tekton Research Inc San Antonio Texas 78240
Tanner Clinic Layton Utah 84041

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04144348, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 2, 2023 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04144348 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →